It operates in the following segments. The International Sales of Branded Generic Pharmaceutical Products is part of the Established Pharmaceutical Products segment.>
- Key Management
Mr. Miles D White (CEO)
~ 43,075 (2021)
~ 113,000 (2021)
Abbott Laboratories is engaged in the discovery, development, and manufacture of a wide variety of healthcare products. It operates in the following segments. The International Sales of Branded Generic Pharmaceutical Products is part of the Established Pharmaceutical Products segment.
The Nutritional Products section focuses on international sales of both adult and pediatric nutrition products. Diagnostic Product is a segment that sells diagnostic products and tests for hospitals, blood banks, and commercial laboratories. Medical Devices cover electrophysiology, cardiac disease, vascular, and structural heart devices that can be used to treat cardiovascular diseases.
It also includes diabetes care products for those with diabetes. The company was founded in 1888 by Wallace Calvin Abbott and has its headquarters in Abbott Park in IL.
Revenue (US$ Mn):
US$ 43,075 Mn was the annual revenue generated by Abbott Laboratories in 2021
Abbott Laboratories’ annual revenue for 2020 was US$ 34,608 Mn, an 8.48% increase from 2019
From 2018’s annual revenues, Abbott Laboratories registered a 4.34% increase in 2019, amounting to US$ 31,904 Mn
Total revenue of US$ 30,578 Mn was generated in 2018 by Abbott Laboratories
Operating Income (US$ Mn):
Abbott Laboratories’ operating income for 2021 was US$ 8,425 Mn, a 57.27% increase from 2020
The operating income generated by Abbott Laboratories in 2020 was US$ 5,357 Mn
At a 24.16% increase, Abbott Laboratories’ operating income of US$ 4,532 Mn was indexed in 2019
Abbott Laboratories generated an operating income of US$ 3,650 Mn in 2018
Net Income (US$ Mn):
US$ 7,071 Mn was Abbott Laboratories’ net income in 2021, a 57.31% increase from 2020 figures
Abbott Laboratories indexed a 21.91% increase in net incomes from 2019, amounting to US$ 4,495 Mn in 2020
Abbott Laboratories generated a net income of US$ 3,687 Mn in 2019
A net income of US$ 2,368 Mn was indexed by Microsoft Corporation in 2018
Operating Margin %:
20% was the operating margin generated by Abbott Laboratories in 2021
Abbott Laboratories’ operating margin for 2020 was 16%, a 9.15% increase from 2019
From 2018’s operating margins, Abbott Laboratories registered a 19.33% increase in 2019, amounting to 14%
An operating margin of 12% was generated in 2018 by Abbott Laboratories
Gross Margin %:
Abbott Laboratories’ gross margin for 2021 was 57%, a 0.71% increase from 2020
The gross margin generated by Abbott Laboratories in 2020 was 57%
At a 0.17% increase, Abbott Laboratories’ gross margin of 59% was indexed in 2019
Abbott Laboratories generated a gross margin of 58% in 2018
Diversified customer base
Abbott sells its products to many customers. The company sells its adult and pediatric nutritional products to individuals, institutions, wholesalers, and retailers, as well as to government agencies, health care facilities, government agencies, third-party distributors, and other healthcare facilities. It sells diagnostics systems at blood banks, hospitals and commercial laboratories, clinics as well as physicians’ offices, government agencies, alternate testing sites, and plasma therapeutic companies.
Distributors, wholesalers, and agencies of Abbott, as well as independent retailers, can access generic pharmaceuticals from the company. Neuromodulation devices are sold to hospitals, physicians’ offices, and ambulatory surgery centers. The company also sells blood glucose monitoring devices, including test strips, sensors, and data management decision software. It also sells accessories to government agencies and wholesalers. The company is able to offer products to different segments, limiting its exposure to risks related to dependence on one customer segment.
Get this premium content